Osteoporosis International

, Volume 16, Issue 12, pp 1989–1998

Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England

  • Beate Aurich Barrera
  • Lynda Wilton
  • Scott Harris
  • Saad A. W. Shakir
Original Article


Risedronate sodium is indicated in postmenopausal women for the prevention and treatment of osteoporosis and for the treatment of Paget’s disease. Our aim was to evaluate the safety of risedronate in a large cohort of patients prescribed risedronate by general practitioners (GPs) in England, soon after it was marketed. An observational cohort study was conducted using the technique of prescription-event monitoring (PEM). Exposure data were obtained from dispensed National Health Service prescriptions issued between September 2000 and June 2002. Outcome data were collected by sending questionnaires to prescribing GPs requesting them to report any events that had occurred since starting risedronate, demographic details, indication, start and stop dates, reasons for stopping, suspected adverse drug reactions (ADRs) and causes of death. Event rates calculated as incidence densities (IDs) separately, for Paget’s disease group and all other patients (osteoporosis group) were ranked and the difference between IDs in month 1 and months 2–6 calculated. The osteoporosis cohort comprised 13,180 patients (10,934 [83.0%] female); median ages for female and male patients were 73 and 69 years, respectively. The most frequently reported event in the first month of treatment was dyspepsia, being also amongst the most frequently reported reasons for stopping risedronate and suspected ADR. Adverse events assessed as possibly or probably related to risedronate included, six of facial edema and one each of Stevens-Johnson syndrome, swollen tongue, palpitation and episcleritis. Risedronate was fairly well tolerated. Adverse events affecting skin, eye, cardiovascular and immunological systems were identified. Prescribing doctors should be aware of these and monitor their patients accordingly.


Adverse events Dyspepsia Episcleritis Prescription-event monitoring Risedronate Stevens-Johnson syndrome 


  1. 1.
    Summary of product characteristics (2000) Actonel 5 mg. Procter and Gamble Pharmaceuticals UK, pp 1–8Google Scholar
  2. 2.
    Summary of product characteristics (2000), Actonel 30 mg. Procter and Gamble Pharmaceuticals UK, 1–6Google Scholar
  3. 3.
    Summary of product characteristics (2003), Actonel once a week 35 mg. Procter and Gamble Pharmaceuticals UKGoogle Scholar
  4. 4.
    Reszka AA, Rodan GA (2003) Bisphosphonate mechanism of action. Curr Rheumatol Rep 5(1):65–74PubMedGoogle Scholar
  5. 5.
    McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344(5):333–340PubMedGoogle Scholar
  6. 6.
    Fogelman I, Ribot C, Smith R, Ethgen D, Sod E, Reginster JY (2000) Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. J Clin Endocrinol Metab 85(5):1895–1900CrossRefPubMedGoogle Scholar
  7. 7.
    Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11(1):83–91PubMedGoogle Scholar
  8. 8.
    Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282(14):1344–1352CrossRefPubMedGoogle Scholar
  9. 9.
    Mortensen L, Charles P, Bekker PJ, Digennaro J, Johnston CC Jr (1998) Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 83(2):396–402CrossRefPubMedGoogle Scholar
  10. 10.
    Clemmesen B, Ravn P, Zegels B, Taquet AN, Christiansen C, Reginster JY (1997) A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis. Osteoporos Int 7(5):488–495Google Scholar
  11. 11.
    Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, Robinson V, Shea B, Wells G, Guyatt G (2002) Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 23(4):517–523CrossRefPubMedGoogle Scholar
  12. 12.
    Miller PD, Brown JP, Siris ES, Hoseyni MS, Axelrod DW, Bekker PJ (1999) A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget’s disease of bone. Paget’s Risedronate/Etidronate Study Group. Am J Med 106(5):513–520CrossRefPubMedGoogle Scholar
  13. 13.
    Brown JP, Hosking DJ, Ste-Marie L, Johnston CC Jr, Reginster J, Ryan WG, Johnson TD, Bekker PJ (1999) Risedronate, a highly effective, short-term oral treatment for Paget’s disease: a dose-response study. Calcif Tissue Int 64(2):93–99CrossRefPubMedGoogle Scholar
  14. 14.
    Brown JP, Chines AA, Myers WR, Eusebio RA, Ritter-Hrncirik C, Hayes CW (2000) Improvement of pagetic bone lesions with risedronate treatment: a radiologic study. Bone 26(3):263–267CrossRefPubMedGoogle Scholar
  15. 15.
    The Royal College of Physicians, The Bone and Tooth Society of Great Britain, The National Osteoporosis Society (2002) Management of glucocorticoid-induced osteoporosis—Guidelines for prevention and treatment. Royal College of Physicians of London, London, pp 1–57Google Scholar
  16. 16.
    Anonymous (2001) Drugs affecting bone metabolism. In: Mehta DK (ed) British National Formulary. British Medical Association and Royal Pharmaceutical Society of Great Britain, London, pp 359–362Google Scholar
  17. 17.
    Reid DM, Adami S, Devogelaer JP, Chines AA (2001) Risedronate increases bone density and reduces vertebral fracture risk within 1 year in men on corticosteroid therapy. Calcif Tissue Int 69(4):242–247CrossRefPubMedGoogle Scholar
  18. 18.
    Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, Doherty SM, Maricic M, Rosen C, Brown J, Barton I, Chines AA (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67(4):277–285CrossRefPubMedGoogle Scholar
  19. 19.
    Eastell R, Devogelaer JP, Peel NF, Chines AA, Bax DE, Sacco-Gibson N, Nagant D, Russell RG (2000) Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int 11(4):331–337Google Scholar
  20. 20.
    Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 15(6):1006–1013PubMedGoogle Scholar
  21. 21.
    Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, Zizic TM, Wallach S, Sewell KL, Lukert BP, Axelrod DW, Chines AA (1999) Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42(11):2309–2318CrossRefPubMedGoogle Scholar
  22. 22.
    Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaisse JM, Clezardin P (2000) Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60(11):2949–2954PubMedGoogle Scholar
  23. 23.
    Reid IR (2003) Bisphosphonates: new indications and methods of administration. Curr Opin Rheumatol 15(4):458–463CrossRefPubMedGoogle Scholar
  24. 24.
    Drake WM, Kendler DL, Brown JP (2001) Consensus statement on the modern therapy of Paget’s disease of bone from a Western Osteoporosis Alliance symposium. Biannual Foothills Meeting on Osteoporosis, Calgary, Alberta, Canada, September 9–10, 2000. Clin Ther 23(4):620–626CrossRefPubMedGoogle Scholar
  25. 25.
    Thomson AB, Marshall JK, Hunt RH, Provenza JM, Lanza FL, Royer MG, Li Z, Blank MA (2002) 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status. J Rheumatol 29(9):1965–1974PubMedGoogle Scholar
  26. 26.
    Taggart H, Bolognese MA, Lindsay R, Ettinger MP, Mulder H, Josse RG, Roberts A, Zippel H, Adami S, Ernst TF, Stevens KP (2002) Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc 77(3):262–270PubMedGoogle Scholar
  27. 27.
    Lanza FL, Rack MF, Li Z, Krajewski SA, Blank MA (2000) Placebo-controlled, randomized, evaluator-blinded endoscopy study of risedronate vs aspirin in healthy postmenopausal women. Aliment Pharmacol Ther 14(12):1663–1670CrossRefPubMedGoogle Scholar
  28. 28.
    Lanza FL, Schwartz H, Sahba B, Malaty HM, Musliner T, Reyes R, Quan H, Graham DY (2000) An endoscopic comparison of the effects of alendronate and risedronate on upper-gastrointestinal mucosae. Am J Gastroenterol 95(11):3112–3117CrossRefPubMedGoogle Scholar
  29. 29.
    Lanza FL, Hunt RH, Thomson AB, Provenza JM, Blank MA (2000) Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 119(3):631–638PubMedGoogle Scholar
  30. 30.
    Vinas G, Olive A, Holgado S, Costa J (2002) Episcleritis secondary to risedronate. Med Clin (Barc) 118(15):598–599Google Scholar
  31. 31.
    Fraunfelder FW, Fraunfelder FT, Jensvold B (2003) Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol 135 (2):219–222CrossRefPubMedGoogle Scholar
  32. 32.
    Rey J, Daumen-Legre V, Pham T, Bernard P, Dahan L, Acquaviva P, Lafforgue P (2000) Uveitis, an under-recognized adverse effect of pamidronate. Case report and literature review. Joint Bone Spine 67(4):337–340PubMedGoogle Scholar
  33. 33.
    O’Donnell N, Rao GP, Aguis-Fernandez A (1995) Paget’s disease: Ocular complications of disodium pamidronate treatment. Br J Clin Pract 49 (5):272–273PubMedGoogle Scholar
  34. 34.
    De S, Meyer P, Crisp AJ (1995) Pamidronate and Uveitis. Br J Rheumatol 34(5):479Google Scholar
  35. 35.
    Macarol V, Fraunfelder FT (1994) Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol 118 (2):220–224PubMedGoogle Scholar
  36. 36.
    Salmen S, Berrueta L, Sanchez N, Montes H, Borges L (2002) Nongranulomatous anterior uveitis associated with alendronate therapy. Invest Clin 43(1):49–52PubMedGoogle Scholar
  37. 37.
    Mbekeani JN, Slamovits TL, Schwartz BH, Sauer HL (1999) Ocular inflammation associated with alendronate therapy. Arch Ophthalmol 117(6):837–838PubMedGoogle Scholar
  38. 38.
    Fraunfelder FW, Fraunfelder FT (2003) Bisphosphonates and ocular inflammation. N Engl J Med 348(12):1187–1188CrossRefPubMedGoogle Scholar
  39. 39.
    Springuel P, McMorran M (2003) Bisphosphonates and ocular disorders; Canadian Adverse Drug Reaction Newsletter. Canada, Health Canada. PamphletGoogle Scholar
  40. 40.
    Shakir SAW (2002) PEM in the UK. In: Mann RD, Andrews EB (eds) Pharmacovigilance. Wiley pp 333–344Google Scholar
  41. 41.
    Venulet J, Bankowski Z (1998) Harmonizing adverse drug reaction terminology: the role of the Council for International Organizations of Medical Sciences. Drug Saf 19(3):165–172PubMedGoogle Scholar
  42. 42.
    Shakir SA (2004) Causality and correlation in pharmacovigilance. In: Talbot PWJ (ed) Stephens’ detection of new adverse drug reactions. Wiley, Chichester, UK, pp 329–343Google Scholar
  43. 43.
    CIOMS.WHO (1993) International guidelines for biomedical research involving human subjects. CIOMS WHO, GenevaGoogle Scholar
  44. 44.
    Royal College of Physicians of London (1996) Guidelines on practice of ethical committees in medical research involving human subjects. Royal College of Physicians of London, pp 1–8Google Scholar
  45. 45.
    Multi-Centre Research Ethics Committee (2000) Guidance notes. Examples of enquiries and surveys in the public interest where no reference to a research ethics committee is necessary. Appendix C:21Google Scholar
  46. 46.
    Heeley E, Riley J, Layton D, Wilton LV, Shakir SA (2001) Prescription-event monitoring and reporting of adverse drug reactions. Lancet 358(9296):1872–1873CrossRefPubMedGoogle Scholar
  47. 47.
    McAvoy BR, Kramer EF (1996) General practice postal surveys: a questionnaire too far? BMJ 313(7059):732–733PubMedGoogle Scholar
  48. 48.
    Biswas PN, Wilton LV, Shakir SA (2003) Pharmacovigilance study of alendronate in England. Osteoporos Int 14:507–514Google Scholar
  49. 49.
    Lichtenberger LM, Romero JJ, Gibson GW, Blank MA (2000) Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa. Dig Dis Sci 45(9):1792–1801PubMedGoogle Scholar
  50. 50.
    Hamilton B, McCoy K, Taggart H (2003) Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 14(3):259–262Google Scholar
  51. 51.
    Blank MA, Gibson GW, Myers WR, Dierckman TA, Phipps RJ, Smith PN (2000) Gastric damage in the rat with nitrogen-containing bisphosphonates depends on pH. Aliment Pharmacol Ther 14(9):1215–1223CrossRefPubMedGoogle Scholar
  52. 52.
    WHO Collaborating Centre for International Drug Monitoring (2002) Caveat document, accompanying statement to data released from the WHO Collaborating Centre. 1. WHO Collaborating Centre for International Drug Monitoring, Uppsala, SwedenGoogle Scholar
  53. 53.
    Bate A, Lindquist M, Edwards IR, Olsson S, Orre S, Lansner A, De Freitas RM (1998) A Bayesian neural network method for adverse drug reaction signal generation . Eur J Clin Pharmacol 54:315–321CrossRefPubMedGoogle Scholar
  54. 54.
    Summary of product characteristics (2005) Actonel 5 mg. Procter and Gamble Pharmaceuticals UK, pp 1–8Google Scholar
  55. 55.
    Summary of product characteristics (2005) Actonel 30 mg. Procter and Gamble Pharmaceuticals UK, pp 1–6Google Scholar
  56. 56.
    Steinbuch M, D’Agostino RB, Mandel JS, Gabrielson E, McClung MR, Stemhagen A, Hofman A (2002) Assessment of mortality in patients enrolled in a risedronate clinical trial program: a retrospective cohort study. Regul Toxicol Pharmacol 35(3):320–326CrossRefPubMedGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2005

Authors and Affiliations

  • Beate Aurich Barrera
    • 1
    • 2
  • Lynda Wilton
    • 1
    • 2
  • Scott Harris
    • 1
    • 3
  • Saad A. W. Shakir
    • 1
    • 2
  1. 1.Drug Safety Research UnitSouthamptonUK
  2. 2.University of PortsmouthPortsmouthUK
  3. 3.University of SouthamptonSouthamptonUK

Personalised recommendations